Meplazumab is an intravenously administered, humanised immunoglobulin G2 monoclonal antibody, targeting CD147 antigen being developed by Pacific Meinuoke Bio Pharmaceutical for the potential prevention and treatment of malaria and for treatment of COVID-19 infections caused due to coronavirus (SARS-CoV-2). It acts as an erythrocytic stage-macromolecular antibody drug that has the potential to mediate both treatment and prophylaxis of falciparum malaria. Clinical development for COVID-19 infections is underway in China while preclinical development is ongoing for malaria in China.
Key Development Milestones
In February 2020, Tang-Du Hospital initiated a phase I/II trial to assess the safety and efficacy of meplazumab in patients with COVID-109 pneumonia (20200101; NCT04275245). The open-label trial intends to enrol approximately 20 patients in China  .
In April 2020, Xijing Hospital (affiliated to Fourth Military Medical University) initiated a phase I trial to assess the safety, tolerability, pharmacokinetics and occupancy characteristics of peripheral blood cell receptors of meplazumab in healthy volunteers, and provide a reference for the dosage of the drug in a phase II clinical trial (MPZ-I-01; NCT04369586). The randomised trial intends to enrol approximately 56 volunteers in China  .
In March 2019, the US FDA granted orphan drug designation to meplazumab for the treatment of malaria  .
Preclinical studies and pharmacological studies have indicated that meplazumab for intravenous (IV) injection is safe and effective with well controlled quality (NCT04327310).